A Multi-center, Open-label, Safety and Tolerability Study of Flexible-dose Oral Aripiprazole (2 mg - 30 mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
